Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Anne Paulison
CONTACT
Lead
University of Minnesota
With
Osteochondral allograft (OCA) transplantation is an established treatment for large focal cartilage and osteochondral defects of the knee. Successful clinical outcomes depend on graft viability, osseous integration, and restoration of the articular surface. Biologic augmentation using bone marrow aspirate concentrate (BMAC) has been investigated as a strategy to improve graft incorporation, but available clinical evidence remains limited and inconsistent. This prospective, single-center pilot case series will evaluate graft incorporation and clinical outcomes following osteochondral allograft transplantation augmented with a combination of Arthrex AlloSync Pure and BMAC. Approximately 10 adult patients scheduled for OCA transplantation of the medial or lateral femoral condyle with Dr. Jeffrey Macalena or Dr. Bradley Nelson will be recruited at the University of Minnesota and M Health Fairview Clinics and Surgery Center. During the planned surgical procedure, bone marrow will be aspirated from the tibial tubercle and processed to obtain BMAC. The BMAC will be mixed with Arthrex AlloSync Pure to create a biologic slurry. This mixture will be applied to the base of the recipient socket and along the walls of the graft plug before implantation of the osteochondral allograft. Participants will be followed for approximately one year after surgery. Follow-up assessments will occur at approximately 1 week, 6 weeks, 12 weeks, 6 months, and 1 year. Patient-reported outcome measures will include the Knee Injury and Osteoarthritis Outcome Score (KOOS) and Visual Analog Scale (VAS) for pain. MRI evaluations will be performed at 12 weeks and 6 months after surgery, with additional MRI at 12 months for participants with incomplete graft incorporation at the 6-month assessment. MRI findings will be evaluated using the Osteochondral Allograft MRI Scoring System (OCAMRISS) and other indicators of graft incorporation. Standard-of-care radiographs will also be reviewed to assess graft healing. The primary outcome is MRI-based osteochondral allograft incorporation at 6 months after surgery. Secondary outcomes include MRI-based incorporation at other follow-up time points, knee function and pain, radiographic healing, postoperative complications, adverse events, and subsequent procedures related to the index surgery. Because this is an exploratory pilot study with a small sample size, outcomes will be summarized descriptively. Observed graft incorporation findings may be compared qualitatively with results reported in the published literature. There is no randomized or concurrent control group.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
